Back to top

Surging Earnings Estimates Signal Good News for Karyopharm Therapeutics (KPTI)

Read MoreHide Full Article

Karyopharm Therapeutics, Inc. (KPTI - Free Report) is a clinical-stage pharmaceutical company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.

These positive earnings estimate revisions suggest that analysts are becoming more optimistic on KPTI’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Karyopharm Therapeutics could be a solid choice for investors.

Current Quarter Estimates for KPTI

In the past 30 days, 7 estimates have gone higher for Karyopharm Therapeutics while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates narrowing from a loss of 82 cents a share 30 days ago, to a loss of 65 cents today, a move of 20.7%.

Current Year Estimates for KPTI

Meanwhile, Karyopharm Therapeutics’s current year figures are also looking quite promising, with 8 estimates moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, narrowing from a loss of $3.22 per share 30 days ago to a loss of $2.86 per share today, an increase of 11.2%.

KARYOPHARM THER Price and Consensus



Bottom Line

The stock has also started to move higher lately, adding 13.3% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #3 (Hold) stock to profit in the near future. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.

Zacks' Top Investment Ideas for Long-Term Profit

How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now.Click here >>

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Karyopharm Therapeutics Inc. (KPTI) - free report >>

More from Zacks Tale of the Tape

You May Like